// App-Quantinova.ai

P061 : Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – IBD Character

Researchers

Presenter

  • A. Adams

Principal Investigators

  • R. Kalla

  • S. Vatn

  • F. Bonfiglio

  • E. Nimmo

  • N. Kennedy

  • N. Ventham

  • M. Vatn

  • P. Ricanek

  • D. Bergemalm

  • J. Halfvarson

  • J. Sderholm

  • M. Pierik

  • L. Trkvist

  • F. Gomoll?n

  • I. Gut

  • J. Jahnsen

  • J. Satsangi

Medical Centers

  • University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom

  • University of Oslo, Institute of Clinical Medicine, EpiGen, Campus Ahus, Oslo, Norway

  • Biocruces Helath Research Institute, Baracaldo, Spain

  • Akershus University Hospital, Department of Gastroenterology, Oslo, Norway

  • Orebro University, Department of Gastroenterology, Faculty of Medicine and Health, Orebro, Sweden

  • Linkoping University Hospital, Dept of Surgery, Linkoping, Sweden

  • Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, The Netherlands

  • Karolinska Institutet, Department of Clinical Science, Intervention and Technology (CLINTEC), Stockholm, Sweden

  • Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

  • CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain

Locations

  • United Kingdom

  • Norway

  • Spain

  • Sweden

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved